⌕
Iradimed · IRMD · Nasdaq
Tenet 67 · Solid
Compare
$83.45−1.64%At closeTenet 67 · Solid
$83.45−1.39 (−1.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Iradimed (IRMD) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~19.0%/yr (FY21→FY25), net margin 26.8%; free cash flow runs at 74% of net income. Check the accrual gap.
The four lines that matter · FY21–FY25
Revenue ($M)▲14.4%
83.8
FY21→FY25CAGR +19.0%/yr
Net income ($M)▲16.9%
22.5
one-off year: see footnoteCAGR +24.6%/yr
Free cash flow ($M)▼1.7%
16.5
FY21→FY25CAGR +12.0%/yr
Diluted EPS▲16.7%
1.75
FY21→FY25CAGR +24.0%/yr
What the receipts whisper · what a headline number hides
Share count
+2.1%

12.6mn → 12.9mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex
$8.4M

steady at 10.0% of revenue (−4.5% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)83.8Revenue−19.5COGS64.3Gross profit−3.0R&D−17.8SG&A26.1Op income−3.7Tax & other22.5Net income

27¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 76.6% → 76.7%. Net margin 26.8% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
89,340.083,814.073,242.065,562.353,303.141,814.6▲14.4%+19.0%
Cost of revenue
21,878.019,490.016,892.015,404.012,020.79,764.7▲15.4%+18.9%
Gross profit
67,462.064,324.056,350.050,158.341,282.432,049.9▲14.2%+19.0%
Research & development
3,288.02,975.02,832.02,858.72,278.11,905.0▲5.0%+11.8%
Selling, general & admin
17,503.017,782.015,937.015,122.110,697.19,771.5▲11.6%+16.1%
Total operating expenses
38,601.038,177.034,385.030,122.825,654.822,232.2▲11.0%+14.5%
Operating incomefeeds ROC rank
28,861.026,147.021,965.020,035.515,627.69,817.7▲19.0%+27.7%
Other income, net
2,256.02,214.02,310.01,702.8553.118.6——
Pretax income
31,117.028,361.024,275.021,738.316,180.79,836.3▲16.8%+30.3%
Income tax
7,132.05,881.05,041.04,545.53,352.3510.8▲16.7%+84.2%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
23,985.022,480.019,234.017,192.812,828.59,325.5▲16.9%+24.6%
Per share
Diluted EPSbuyback-sensitive
1.871.751.501.351.020.74▲16.7%+24.0%
Diluted shares (mn)
12.8812.8512.7812.7212.6412.59▲0.5%+0.5%
Margins
Gross margin68th pct in Healthcare
75.5%76.7%76.9%76.5%77.4%76.6%▼0.2pp+0.1pp
Operating margin
32.3%31.2%30.0%30.6%29.3%23.5%▲1.2pp+7.7pp
Net margin91st pct in Healthcare
26.8%26.8%26.3%26.2%24.1%22.3%▲0.6pp+4.5pp
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 5% vs a 21% norm for this window, likely a one-time item; see the filing.
FY13 – FY20 · 8 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 8 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-06 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Iradimed's revenue last fiscal year?

Iradimed reported revenue of $83.8M in fiscal 2025, up 14.4% from fiscal 2024.

What was Iradimed's net income?

Iradimed reported net income of $22.5M in fiscal 2025, a net margin of 26.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.